



## Application of artificial intelligence to thyroid diseases and their management

Dr. Nilamadhaba Prusty<sup>1</sup>, Dr. Ansuman Pradhan<sup>2</sup>, Dr. Dilip Kumar Pradhan<sup>3</sup>,  
Dr. Dillip Kumar Chand<sup>4</sup>

<sup>1</sup>Associate Professor, Department of ENT, FM MCH, Balasore

<sup>2</sup>Assistant Professor, Department of Surgery, SJ MCH, Puri

<sup>3</sup>Assistant Professor, Department of Medicine, PRM MCH, Baripada

<sup>4</sup>Assistant Professor, Department of Orthopaedics, SJ MCH, Puri

**Corresponding Author:** Dr. Dillip Kumar Chand, Assistant Professor, Department of Orthopaedics, SJ MCH, Puri

Volume 6, Issue 13, Aug 2024

Received: 15 June 2024

Accepted: 25 July 2024

Published: 15 Aug 2024

[doi:10.48047/AFJBS.6.13.2024.6069-6078](https://doi.org/10.48047/AFJBS.6.13.2024.6069-6078)

### Abstract:

Artificial intelligence (AI) is transforming healthcare and offers new tools in clinical research, personalized medicine, and medical diagnostics. Thyroid function tests represent an important asset for physicians in the diagnosis and monitoring of pathologies. Artificial intelligence tools can clearly assist physicians and specialists in laboratory medicine to optimize test prescription, test interpretation, decision-making, process optimization, and assay design. Our article is reviewing several of these aspects. As thyroid AI models rely on large data sets, which often require distributed learning from multi-center contributions, this article also briefly discusses this issue.

**Keywords:** artificial intelligence; biomarkers; clinical decision support systems; digital health; thyroid diseases

### Introduction

The thyroid is a crucial endocrine organ in the human body. Thyroid cancer, one of the most prevalent endocrine system malignancies, accounts for the largest proportion of head and neck cancers. [1] It consists of two connected lobes and is one of the largest endocrine glands in the human body, weighing 20–30 g in adults. Thyroid lesions are often found on the gland, with a prevalence of 4–7%. Most of them are symptomatic, and thyroid hormone secretion is normal. [2] Thyroid cancer (TC) is a common malignant tumor of the head and neck. The incidence of malignant tumors is seventh, ranked fourth in the incidence in women. [3] The histologic types can be divided into papillary carcinoma and Papillary Thyroid Carcinoma (PTC), Follicular Cancer, Medullary Cancer, and Undifferentiated cancer. PTC is the most common one, accounting for 80–88%. [4]

The term artificial intelligence (AI) was first used in 1956 by John McCarthy, who used his work on neural networks to solidify the orientation of the field. [5] Artificial

intelligence (AI) is a field of computing science mimicking the human thought processes and behaviors used to make decisions or take actions [6]. It uses different mathematical and algorithmic approaches, from operational research to constrained programming [6]. Artificial intelligence is transforming healthcare and offers new promising solutions in clinical examination, precision medicine, research, and clinical diagnostics [6–9]. The expectations associated with AI are growing exponentially as the volume of medical data available (electronic medical records, laboratory informatics systems, omics, mobile health applications, *etc.*) is constantly increasing [10]. In the field of laboratory medicine, automation and digitalization are stimulating the use of AI and the evolution of laboratory services [7–8]. Artificial intelligence also allows disorders and outcome forecasts based on routine laboratory analysis and understanding of complex biochemical information [11].

Since its inception, many industries have integrated artificial intelligence into their work environments. The healthcare sector mainly uses natural language processing to drive the conceptualization and classification of clinical documents. [12] Learning algorithms can improve precision and accuracy when interacting with training information. Such programming allows humans to better understand disease diagnosis, care procedures, rehabilitation variability, and patient outcomes. According to Hamet and Tremblay, AI in medicine comprises two domains: the virtual domain involves informatics approaches, while the physical domain encompasses the robots used to conduct procedures. [13] Understanding the association between AI and medicine is vital to learning the benefits and shortcomings.

AI provides numerous advantages in healthcare over traditional approaches since it enhances the analytical process and the techniques to facilitate decision-making. Additionally, the topic of explainable AI or interpretable AI is growing in popularity, as it is reasonable to foresee that AI will be an integral part of the future of the medical field. Computer-based programs using AI have been successfully used in many applications related to the brain, breast, and lung. [14-16] Learning algorithms can improve precision and accuracy when interacting with training information. Such programming allows humans to better understand disease diagnosis, care procedures, rehabilitation variability, and patient outcomes. According to Hamet and Tremblay, AI in medicine comprises two domains: the virtual domain involves informatics approaches, while the physical domain encompasses the robots used to conduct procedures. [13] Understanding the association between AI and medicine is vital to learning the benefits and shortcomings. AI provides numerous advantages in healthcare over traditional approaches since it enhances the analytical process and the techniques to facilitate decision-making. Additionally, the topic of explainable AI or interpretable AI is growing in popularity, as it is reasonable to foresee that AI will be an integral part of the future of the medical field. Computer-based programs using AI have been successfully used in many applications related to the brain, breast, and lung. [14-16]

Thyroid hormones are fundamental for development, neuronal growth, fertility, and metabolism [1]. Thyroid diseases are frequent conditions, affecting millions of people around the world, related to multiple health problems, and for which thyroid function

tests (TFT) are frequently ordered for the diagnosis and monitoring of diseases [18]. The main aim of this study is to review some of the potential applications of AI in thyroid function tests.

## **Material and Method**

### **The application of AI to thyroid disorders: preliminary observations from radiology and imaging**

The complexity of the diagnosis of some thyroid pathologies has stimulated the development of AI solutions to assist physicians. Different examples coming from the fields of radiology and imaging can illustrate this trend. A first observation is that using AI-based computerized diagnosis systems can personalize and optimize the management of thyroid nodules. Because of clinical requests to diminish superfluous fine needle aspiration (FNA), AI-based solutions have been proposed as ways of expanding the exactness of ultrasonography-based conclusions for less-experienced administrators and to address the intricacy of the fragmented risk stratification systems [19].

A second observation is the possibility of staging malignancy of thyroid tumors and how deep learning AI models can help to differentiate between malignant tumors and benign thyroid tumors based on distinctive clinical and ultrasonographic characteristics [20]. Artificial intelligence algorithms have been utilized for the classification of thyroid nodules utilizing ultrasound pictures, cytopathology pictures, and molecular markers [21]. Interestingly, the accuracy of the AI model was superior to that of radiologists for diagnosing malignancy and was leading to significant reduction of FNA [19]. Published data showed that neural network precision in segregating advanced *versus* non-advanced thyroid carcinomas was 84%, with positive and negative predictive values of 87% and 92%, respectively [22].

The use of AI to determine tumor classification is also an important step in the choice of an optimum treatment [21]. A third observation is the application of AI for the automation of image analysis with whole-slide imaging [23]. A recent study reported that the coefficients of correlation with manual evaluation were higher than 0.76 and that the diagnosis performance of the AI-based robotized models was similar to a specialist pathologist analysis [23].

### **The application of AI to laboratory medicine: considerations for thyroid function tests**

Thyroid function tests represent an important asset for physicians in the diagnosis and monitoring of thyroid pathologies. Artificial intelligence applications have the potential to optimize correct test prescription, test interpretation, decision-making, process optimization, and assay design (Figure 1). We will discuss some of these perspectives at the pre-analytical, analytical, and post-analytical levels.

### **Impact on preanalytical factors and process optimization**


An important aspect of the preanalytical phase is the appropriate test ordering by physicians. Guiding the physicians in the ordering of the right TFT according to clinical context is important, especially in a context where the overuse of TFT has been documented in both hospital and primary care practices [24]. The optimal choice of TFT is important to make effective clinical decisions and to help physicians spend more time treating patients [25]. In contrast, excessive TFT ordering policies can cause financial strain in a period of rising medical care costs. Artificial intelligence-based companions have the potential to help physicians optimize TFT prescriptions and define intelligent order sets that can contribute to reducing laboratory overutilization [24]. A recent study investigated the value of a deep learning-based automated system to recommend appropriate laboratory tests [25]. The AI-based model achieved a higher area under the receiver operating characteristics curve (AUROC micro = 0.98 and AUROC macro = 0.94). The integration of such an AI companion into existing workflows can reduce under- and over-utilization of TFT [26]. Clinical laboratories are still in important phases of consolidation and automation, with emphasis also placed on the preanalytical levels and sample transportation. Clinical laboratories also constantly work on the improvement of patients' experiences and laboratory services. Artificial intelligence can possibly upgrade all degrees of testing work processes and test assortment, including work process enhancement and operational efficiency [27–28]. Artificial intelligence tools can also have applications to assist medical teams with matrix selection at the time of tube collection, recommendations of an adequate moment for sampling, and the integration of variables to control and monitor the transportation of samples.

### **Impact on the analytical phase**

Improvement of TFT assays remains an objective for the clinical community and for scientific societies [28]. The standardization is also still ongoing from the perspective of better commutability of results and clinical cut-off points between laboratories [29]. However, several challenges are still paving the way, and the use of AI for the *in silico* design of TFT assays can offer an additional solution to go forward [30]. *In silico* modeling can enhance the know-how of TFT assays and technology capabilities with perspectives of increased efficiency and robustness of assays, reduction of time-to-market, and streamline of operations and production. *In silico* approaches can be applied to immunoassays for epitope prediction, the simulation of optimized assay sequences and formats, and the validation of novel proofs of concept at the bioprocessing level. Additionally, as TFTs are still prone to interference with consequences for patients, as up to half of recorded thyroid obstructions prompted misdiagnosis or potentially unseemly administration, including the remedy of a superfluous treatment, the *in silico* design can significantly decrease the sensitivity to interfering compounds and improve TFT assays [32].

### **Impact on the post-analytical phase**

The definition of personalized reference intervals is important for the appropriate use of TFT. The use of data mining and AI approaches can help clinical laboratory teams establish or verify reference intervals for TFT by extracting and integrating data from laboratory informatic systems and electronic medical records [32]. A large amount of data can be processed, and reference intervals can be more accurately adjusted to different population subgroups.



**Figure 1.** The perspectives associated to the integration of AI and thyroid function tests.

Thyroid function test variability within and between subjects is high with the example of TSH concentrations, which can change over the long run inside a person because of different internal and outer elements [33]. Artificial intelligence tools could also be seen as additional options to better estimate and derive biological variability by diving into clinical databases to identify sources of fluctuations for TFT and therefore adjust the decision limit accordingly [34]. Recent data showed that AI and machine learning methods might offer unique insight into the complex hypothalamic-pituitary-thyroid axis, identify factors determining individual TSH concentration, and may be relevant tools that guide us in making appropriate therapeutic decisions for the individual patient [35].

### **Clinical decision support systems**

Clinical decision support systems (CDSS) are designed to utilize medical data, knowledge, and analysis engines to generate patient-specific assessments or recommendations to health professionals in order to assist in decision-making [36]. Artificial intelligence can enable CDSS to aid the decision-making process for thyroid diseases through an intelligent component. The building of CDSS for the interpretation of TFT and image signals will provide integrated approaches to support clinical decisions regarding thyroid diseases and the integration of clinical practice guidelines. Clinical decision support systems using machine learning-evaluated

geometric and morphological features have already been evaluated for the classification of thyroid nodules [37]. The COVID-19 pandemic also triggers the development of CDSS using imaging techniques and biomarkers for mortality prediction [38]. The same strategy could be applied to thyroid cancer, using the progress of AI to separate and break down morphological, textural, and molecular features [39]. Clinical decision support systems might help physicians accelerate the decision-making process for thyroid diseases. Another example is the potential use of AI-based CDSS for diagnosis and estimating the risk of the development of thyroid autoimmune disease [40]. Using AI-based CDSS for potential autoimmune thyroid pathobiology will rely on the integration of complex datasets coming from genetic (human leukocyte antigen (HLA) and other genes), environmental (different triggers (viruses, microbes), and immune system characteristics (autoantibodies, cytokines) [41–42]. This could be particularly relevant to distinguishing different types of thyroid autoimmune diseases, such as autoimmune thyroiditis, Hashimoto thyroiditis, Hashimoto disease, or Grave disease, with different patterns of hyperthyroidism or hypothyroidism. The application of AI in autoimmune diseases in most recent studies has focused on patient identification, hazard expectation, finding, disorder subtype, evolution, and complications [40]. A diagnosis solution based on an artificial immune recognition system with balanced preprocessing is one of the most promising future methods for evaluating thyroid diseases [41].

### **Challenges and additional perspectives Challenges**

In order to achieve the clinical benefits of using AI for thyroid pathology and for optimized use of TFT, several challenges must be considered [43]:

- Establish a comprehensive legal framework for AI and update existing relevant legislation to ensure that it is fit for purpose.
- Identify and promote best practices ensuring the robustness of big data and AI systems in the health sector, both at the stages of development and actual use, to reduce potential biases and errors in AI-based decision-making.
- Improve data interoperability and support the development of data infrastructure, with the goal of providing reliable flow data with standardized formats, the necessary cybersecurity provisions, and data protections.
- Support the development of national electronic health records and improve the interoperability of health data.
- Stimulate scientific research and development in the field to boost the updates of AI applications in healthcare and support patient access to the best available technologies.
- Equip the workforce with the necessary skill sets to maximize the positive impact of AI and conduct a comprehensive regulatory assessment of the medical profession's frameworks to determine whether they are fit for the use of patient-centered AI in healthcare provision.
- Ensure that AI is applied with full respect to data protection rules while observing the balance between scientific advancement and patient protection.

- Put in place mechanisms to ensure educational assistance for patients to allow them to better understand and use AI and empower them to actively participate in the management of their health.
- Define the value and business models around AI tools and carefully assess the benefits in terms of clinical outcomes, patient experience, and costs.
- Encourage the active involvement of healthcare work forces in the construction and validation of AI solutions and decision support systems.

### **Continuous learning in secure multi-centric coalitions**

Although recent research results have shown effective and promising results obtained by AI models for diagnosis, classification, and clinical decision support for the treatment of thyroidal disorders, the deployment of these models must adapt to the variability of data acquisition across clinical environments. Therefore, the use of continual learning models that adapt to local clinical practices must be triggered. Such models should be promoted within coalitions of hospitals sharing the same practices and guidelines. A solution to provide efficient, reliable, and privacy-preserving distributed learning inside a coalition of hospitals has been previously described. [44]

### **Network medicine**

Thyroid pathology encompasses a heterogeneous group of clinical-pathological entities [39]. Network medicine offers the possibility to integrate multiomics data with very well-characterized clinical phenotypes to work on the comprehension of complex diseases [45]. Using AI to apply network medicine to thyroid pathobiology will rely on the integration of complex datasets coming from hyperspectral mass spectrometry imaging, from the molecular signatures of thyroid tumors, from proteomic analysis, and from transcriptomes or other multi-omics networks [46–48]. The combination of AI and network medicine will contribute to a superior comprehension of thyroid disorders and the improvement of upgraded diagnostic and treatment options by eliciting causal relationships in the biological continuum, from molecular omics data to histology [49].

### **Conclusion**

Artificial intelligence is becoming a useful tool to assist in the in the diagnosis and risk classification of thyroid diseases. Artificial intelligence companions can significantly improve the performance of clinical laboratories for process optimization as well as provide support for clinical decisions. Artificial intelligence tools offer *in vitro* diagnostic companies' novel options for the design and improvement of TFT. The incorporation of AI into clinical pathways also offers opportunities to enhance care. Pathways, laboratory tests, prescriptions, clinical diagnosis, and patients' outcomes. In the context of network medicine, AI will help to better understand complex thyroid diseases, detect molecular mechanisms, and develop potential new treatment strategies.

### **Reference**

1. Alexander EK, Cibas ES. Diagnosis of thyroid nodules. *Lancet Diabetes Endocrinol.* 2022;10(7):533-539.

2. Mulita F., Anjum F. *Thyroid Adenoma*. Treasure Island (FL): StatPearls Publishing, 2023.
3. Aversano L, Bernardi ML, Cimitile M, A systematic review on artificial intelligence techniques for detecting thyroid diseases, *PeerJ Comput Sci* 9:e1394, 2023.
4. Issa PP, Munshi R, Albuck AL, Recommend with caution: A meta-analysis investigating papillary thyroid carcinoma tumor progression under active surveillance, *Amer J Otolaryngol* 103994:718–732, 2023.
5. Dhamija P., Bag S. Role of artificial intelligence in the operations environment: a review and bibliometric analysis. *The TQM J.* 2020;32(4):869–
6. Gruson D, Helleputte T, Rousseau P, and Gruson D. *Data science, artificial intelligence, and machine learning: opportunities for laboratory medicine and the value of positive regulation.* *Clin Biochem.* 2019;69:1–7.
7. Paranjape K, Schinkel M, Hammer RD, et al. *The Value of Artificial Intelligence in Laboratory Medicine.* *Am J Clin Pathol.* 2021;155:823–31.
8. De Bruyne S, Speeckaert MM, van Biesen W, et al. *Recent evolutions of machine learning applications in clinical laboratory medicine.* *Crit Rev Clin Lab Sci.* 2021;58:131–52.
9. *Artificial Intelligence in Healthcare | Health First Europe.* Available from: <https://healthfirsteurope.eu/publication/compendium-artificial-intelligence-in-healthcare>.
10. Schwalbe N, Wahl B. *Artificial intelligence and the future of global health.* *Lancet.* 2020;395:1579–86.
11. Gruson D, Bernardini S, Dabla PK, et al. *Collaborative AI and Laboratory Medicine Integration in Precision Cardiovascular Medicine* *Clinica Chimica Acta.* 2020;509:67–71.
12. Delivering clinical impact with artificial intelligence. *BMC Medicine.* 2019;17(1).
13. Hamet P, Tremblay J. *Artificial intelligence in medicine.* *Metabolism.* 2017 Apr 1;69: S36–S40.
14. Havaei M., Davy A., Warde-Farley D., et al., *Brain Tumor Segmentation with Deep Neural Networks.* *Medical Image Analysis.* 2017;35:18–
15. Li Y, Zhang L, Chen H, and Yang N. *Lung Nodule Detection With Deep Learning in 3D Thoracic MR Images.* *IEEE Access.* 2019;7:37822–
16. Moon WK, Huang YS, Lee YW, et al. *Computer-aided tumor diagnosis using shear wave breast elastography.* *Ultrasonics.* 2017;78:125–
17. Taylor PN, Albrecht D, Scholz A, et al. *Global epidemiology of hyperthyroidism and hypothyroidism.* *Nat Rev Endocrinol.* 2018;14:301–16.
18. Kluesner JK, Beckman DJ, Tate JM, et al. *Analysis of current thyroid function test ordering practices.* *J Eval Clin Pract.* 2018;24:347–52.
19. Peng S., Liu Y., Lv W., et al. *A deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study.* *Lancet Digit Health.* 2021;3:e250–9.



20. Cordes M, Götz TI, Lang EW, et al.. *Advanced thyroid carcinomas: neural network analysis of ultrasonographic characteristics. Thyroid Res.* 2021;14.
21. Thomas J., Ledger GA, and Mamillapalli CK. *Use of artificial intelligence and machine learning for estimating the malignancy risk of thyroid nodules. Curr Opin Endocrinol Diabetes Obes.* 2020;27:345–50.
22. Wang Y, Yue W, Li X, et al. *Comparison Study of Radiomics and Deep Learning-Based Methods for Thyroid Nodule Classification Using Ultrasound Images. IEEE Access.* 2020;8:52010–7.
23. Girolami I, Marletta S, Pantanowitz L, et al. *Impact of image analysis and artificial intelligence in thyroid pathology, with particular reference to cytological aspects. Cytopathology.* 2020;31:432-44.
24. Crampton N, Kalia S, Del Giudice ME, et al. *Over-use of thyroid testing in Canadian and UK primary care among frequent attendees: A cross-sectional study. Int J Clin Pract.* 2021;75:e14144.
25. Islam MM, Poly TN, Yang HC, and Li YC. *Deep into Laboratory: An Artificial Intelligence Approach to Recommend Laboratory Tests. Diagnostics (Basel).* 2021;11:990.
26. Harmon E, Blackwell JN, Pan JA, et al. *Implementation of a Novel Order Set to Improve Baseline Pulmonary, Hepatic, and Thyroid Function Testing at the Time of Inpatient Amiodarone Initiation. Am J Cardiol.* 2020;136:173–5.
27. Letourneau-Guillon L, Camirand D, et al.. *Artificial Intelligence Applications for Workflow, Process Optimization, and Predictive Analytics. Neuroimaging Clin N Am.* 2020;30(4):e1–15.
28. Kovalchuk SV, Funkner AA, Metsker OG, et al. *Simulation of patient flow in multiple healthcare units using process and data mining techniques for model identification. J Biomed Inform.* 2018;82:128–42.
29. Kratzsch J, Baumann NA, Ceriotti F, et al. *Global FT4 immunoassay standardization: an expert opinion review. Clin Chem Lab Med.* 2020;59:1013–23.
30. Ahsan H. *Monoplex and multiplex immunoassays: approval, advancements, and alternatives. Comp Clin Path.* 2022;31:333–45.
31. Favresse J, Burlacu M-C, Maiter D, et al. *Interferences with thyroid function immunoassays: clinical implications and detection algorithm. Essential points.* 2018;39:830-50.
32. Ma C., Cheng X., Xue F, et al. *Validation of an approach using only patient big data from clinical laboratories to establish reference intervals for thyroid hormones based on data mining. Clin Biochem.* 2020;80:25–30.
33. Mairesse A., Wauthier L., Courcelles L., et al. *Biological variation and analytical goals of four thyroid function biomarkers in healthy European volunteers Clin Endocrinol (Oxf).* 2021;94:845–5.
34. Wang D., Cheng X., Yu S., et al. *Data mining: seasonal and temperature fluctuations in thyroid-stimulating hormone. Clin Biochem.* 2018;60:59–63.

35. Santhanam P, Nath T, Mohammad FK, and Ahima RS. Artificial intelligence may offer insight into factors determining individual TSH levels. *PLoS One*. 2020;15:e0233336.
36. Ji M, Genchev GZ, Huang H, et al. Evaluation Framework for Successful Artificial Intelligence-Enabled Clinical Decision Support Systems: A Mixed Methods Study. *J Med Internet Res*. 2021;23:e25929.
37. Gomes Ataíde EJ, Ponugoti N, et al. Thyroid Nodule Classification for Physician Decision Support Using Machine Learning-Evaluated Geometric and Morphological Features. *Sensors (Basel)*. 2020;20:6110.
38. Karthikeyan A, Garg A, Vinod PK, et al. Machine Learning-Based Clinical Decision Support System for Early COVID-19 Mortality Prediction. *Front Public Health*. 2021;9:626697.
39. Li LR, Du B, et al. Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives. *Front Oncol*. 2021;10:604051.
40. Stafford IS, Kellermann M, Mossotto E, et al. systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases. *NPJ Digit Med*. 2020;3:30.
41. Polat K, Şahan S, and Güneş S. A novel hybrid method based on an artificial immune recognition system (AIRS) with fuzzy weighted pre-processing for thyroid disease diagnosis. *Expert Systems with Applications: An International Journal*. 2007;32:1141–
42. Ahmad W, Ahmad A, Lu C, et al. A novel hybrid decision support system for thyroid disease forecasting. *Soft Computing*. 2018;22:5377–83.
43. Gruson D. Big Data, artificial intelligence, and laboratory medicine: time for integration. *Advances in Laboratory Medicine/Avances en Medicina de Laboratorio [Internet]*. 2021 Mar 1 [cited 2022 Apr 3];2(1):1–3.
44. Lugan S, Desbordes P, Brion E, et al., Secure Architectures: Implementing Trusted Coalitions for Blockchain Distributed Learning (TCLearn). *IEEE Access*. 2019;7:181789–99.
45. Lee LY, Pandey AK, et al. Network medicine in cardiovascular research. *Cardiovasc Res*. 2021;117:2186–202.
46. Gardner W, Cutts SM, Phillips DR, et al. Understanding mass spectrometry images: complexity to clarity with machine learning. *Biopolymers*. 2021;112:e23400.
47. Hernandez-Prera, JC. Molecular Pathology of Thyroid Tumors: Old Problems and New Concepts. *Surg Pathol Clin*. 2021;14:493-506.
48. Temiz Karadag D, Cetinarslan B, Kasap M, et al. Proteomic analysis of thyroid tissue reveals enhanced catabolic activity in Graves' disease compared to toxic multinodular goiters. *Cell Biochem Funct*. 2021;39:658–66.
49. Gulfidan G., Soylu M., Demirel D., et al. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multiomic networks. *Arch Biochem Biophys*. 2022;715:109085.